Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Porter

Showing results (191-200 of 199) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 199 results.
Nature Biomedical Engineering|March 10, 2026
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancerGregory M Chen, Ankita Jain, David T Gering, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 22, 2018
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow TransplantationAnkit J Kansagra, Noelle V Frey, Merav Bar, et al.
Bone Marrow Transplantation|May 17, 2019
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)Ankit J Kansagra, Noelle V Frey, Merav Bar, et al.
Science Advances|November 13, 2024
TET2 regulates early and late transitions in exhausted CD8<sup>+</sup> T cell differentiation and limits CAR T cell functionAlexander J Dimitri, Amy E Baxter, Gregory M Chen, et al.
Nature Medicine|March 15, 2022
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Anqi Dai, Guido Ghilardi, et al.
Nature Medicine|October 17, 2022
Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Anqi Dai, Guido Ghilardi, et al.
Journal for Immunotherapy of Cancer|December 27, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemiaMichael Boyiadzis, Michael R Bishop, Rafat Abonour, et al.
Nature Medicine|January 15, 2026
CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapyMatthew Ho, Luca Paruzzo, Julia Han Noll, et al.
Nature Medicine|January 20, 2025
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapiesJulie K Jadlowsky, Elizabeth O Hexner, Amy Marshall, et al.
Pageof 20

Showing results (191-200 of 199) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 199 results.
Nature Biomedical Engineering|March 10, 2026
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancerGregory M Chen, Ankita Jain, David T Gering, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 22, 2018
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow TransplantationAnkit J Kansagra, Noelle V Frey, Merav Bar, et al.
Bone Marrow Transplantation|May 17, 2019
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)Ankit J Kansagra, Noelle V Frey, Merav Bar, et al.
Science Advances|November 13, 2024
TET2 regulates early and late transitions in exhausted CD8<sup>+</sup> T cell differentiation and limits CAR T cell functionAlexander J Dimitri, Amy E Baxter, Gregory M Chen, et al.
Nature Medicine|March 15, 2022
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Anqi Dai, Guido Ghilardi, et al.
Nature Medicine|October 17, 2022
Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Anqi Dai, Guido Ghilardi, et al.
Journal for Immunotherapy of Cancer|December 27, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemiaMichael Boyiadzis, Michael R Bishop, Rafat Abonour, et al.
Nature Medicine|January 15, 2026
CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapyMatthew Ho, Luca Paruzzo, Julia Han Noll, et al.
Nature Medicine|January 20, 2025
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapiesJulie K Jadlowsky, Elizabeth O Hexner, Amy Marshall, et al.
Pageof 20